<DOC>
	<DOCNO>NCT00372762</DOCNO>
	<brief_summary>Patients NYHA FC II-III heart failure randomize cross-over fashion 8 week bumetanide versus furosemide therapy ( equipotent dose ) , test whether bumetanide therapy superior effect insulin resistance compare furosemide . Patients subject frequently sample intravenous glucose tolerance test ( FSIGT ) minimal model ( MINMOD ) analysis assess insulin resistance 6-minute walk test ( 6MWT ) ass functional capacity ; patient recruitment retention success , well medication adherence , also assess .</brief_summary>
	<brief_title>Bumetanide Versus Furosemide Heart Failure</brief_title>
	<detailed_description>Insulin resistance common patient heart failure ( HF ) associate bad functional capacity severe symptoms heart failure . The majority HF patient take furosemide least daily basis symptom relief . Bumetanide loop diuretic similar therapeutic diuretic effect furosemide . There evidence observational small comparative trial bumetanide significantly less deleterious effect indirect measure insulin resistance compare furosemide . However , formal comparison 2 drug use rigorous measure insulin resistance never conduct patient HF . If bumetanide demonstrate similar diuretic superior ( less deleterious ) effect insulin resistance patient HF , potential exists bumetanide significantly reduce morbidity patient heart failure compare furosemide . In order prepare study , variance MINMOD-derived insulin resistance FSIGT ( 26 ) , group patient need determine along feasibility conducting study . Functional capacity determine duplicate 6-minute walk test .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Bumetanide</mesh_term>
	<criteria>1 . Men woman ≥18 year age 2 . NHYA FC II III HF AND document LVEF ≤40 % within 6 month prior study entry 3 . Taking 20 mg 80 mg furosemide orally twice per day 4 . No change cardiac medication 3 month prior study entry anticipate change medication duration study 5 . No change oral antidiabetic medication ( applicable ) 3 month prior study entry , anticipate change duration study ( metformin , sulphonylurea type , glitazone type ) 6 . Ability provide write consent 1 . Known sensitivity bumetanide 2 . Myocardial infarction , coronary angioplasty , coronary artery bypass surgery , admission HF unstable angina within 3 month period prior study recruitment 3 . Planned coronary intervention within 6 month 4 . Patients take insulin 5 . Patients chronic renal ( serum creatinine ≥ 200 μmol/L ) hepatic impairment ( know cirrhosis AST ALT &gt; 1.5 x upper limit normal )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Insulin resistance</keyword>
	<keyword>heart failure</keyword>
	<keyword>diuretic therapy</keyword>
</DOC>